Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AELIX-003: HTI Vaccines and Vesatolimod in Early Treated HIV-1
NCT04364035Phase 2Completed
- Sponsor
- Aelix Therapeutics
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of ChAdOx1.HTI, MVA.HTI, vesatolimod in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Aelix Therapeutics. Started Feb 2020; status: completed.
02
Drugs
ChAdOx1.HTIMVA.HTIvesatolimod
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04364035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364035.